Someday, it may be possible to take just one pill a week for conditions as varied as Alzheimer’s, addiction, allergies, malaria, schizophrenia, high cholesterol, and HIV.
That was Lyndra’s pitch, anyway. Now, the Watertown, Mass.-based biotech is promoting its first set of clinical data to back up those promises.
It’s still very early, but if the company succeeds, its product may tackle a perpetual problem: medication adherence. Many people don’t take their pills as prescribed for a variety of reasons — because they’re nervous about side effects or it’s too expensive or it’s too difficult to keep track of a given regime, for example. But some researchers have found that more people stick to the program when they only have to take a drug once a week rather than every day.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
